瑞波西汀与度洛西汀治疗伴躯体症状抑郁症的疗效  

Efficacy and Safety of Reboxetine in the Treatment of Depression with somatic symptoms

作　　者：刘秀苹[1] 赵子军[1] 雷彤[1] 

机构地区：[1]天津市安定医院九科,天津300222

出　　处：《中国城乡企业卫生》2012年第5期27-28,共2页Chinese Journal of Urban and Rural Enterprise Hygiene

摘　　要：目的评价瑞波西汀治疗伴有躯体症状抑郁症的疗效及安全性。方法将66例伴有躯体症状抑郁症患者随机分为瑞波两汀组33例和度洛两汀组33例，治疗剂量分别为8-12mg／d和40-60mg／d，均治疗8周。用汉密尔顿抑郁量表评定其疗效，用不良反应量表评定其不良反应和安全性。结果两组疗效差异无统计学意义，HAMD总分及治疗后2-8周均较治疗前显著降低，两组问比较差异无统计学意义，不良应差异亦无统计学意义。结论瑞波西汀对治疗伴躯体症状的抑郁疗效好、安全，适于临床使用。Objective To evaluate the efficacy and safety of reboxetine in the treatment of depression with somatic symptoms. Methods A total of 66 patients with depression of somatic symptoms were divided into reboxetine group（n=33） and duloxetine group （n=33）.The patients were treated with reboxetine （8-12mg/d）or duloxetine （40-60 mg/d） for 8 weeks.The efficacy was assessed with Hamilton Their efficacy were evaluated by Hamilton Depresaine Seale（HAMD 17）and their adverse reactions were evaluated by the Treatment Emergent Symptom Scale （TESS）. Results The efficacy of reboxetine and duloxetine were nearly equal. No significant differences were observed in efficacy and incidence of adverse reactions between two groups. Conclusion Re boxetine is an effective and safe drug for depression with somatic symptoms, and can use in clinical.

关 键 词：瑞波西汀 度洛西汀 伴有躯体症状抑郁症 

分 类 号：R454.3[医药卫生—治疗学]